PRODUCT OVERVIEW

Creator™ SMART™ Library Construction Kit

Combining the best of both worlds

- Unique SMART™ cDNA synthesis results in full-length cDNA
- No adaptor ligation required for cDNA cloning
- Swiftly transfer your library inserts into expression vectors for use functional studies

We have united our SMART™ and Creator™ technologies in our Creator™ SMART™ cDNA Library Construction Kit to bring you the fastest and easiest method for accurate and representative library construction. SMART technology is the best way to synthesize full-length cDNA from very small quantities of RNA. Creator allows you to shuttle full-length inserts between different expression vectors.

Generate full-length cDNA libraries
Our SMART (Switching Mechanism At the 5′ end of RNA Transcript) technology allows you start with only 2 µg of total RNA to generate a library. This patented method uses a SMART Oligo and reverse transcriptase to make a universal priming site on the 5′ end of the newly synthesized first-strand cDNA (Figure 1). Second-strand synthesis is easily accomplished using primer extension or PCR with the universal primers. We have also introduced the rare restriction site for Sfi I into these universal primers so it is easy to directionally insert the cDNA into the Creator pDNR-LIB Library Vector.

The fastest way to functional studies
Our Creator pDNR-LIB Vector was designed for easy handling in bacteria and effortless transfer of your gene of interest from the library vector to any Creator-compatible expression vector. Once you have identified positive clones, simply combine each clone with the expression vectors of your choice and Cre recombinase to generate expression clones containing your genes.

The foundation for the Mammalian Gene Collection Project
The Creator SMART cDNA Library Construction Kit was used to make the Creator SMART cDNA Libraries, which serve as the foundation of the new Mammalian Gene Collection (MGC) Project, a joint effort of the National Institutes of Health (NIH) and the National Cancer Institute (NCI). This project aims to provide researchers with a full set of inexpensive, full-length clones and sequences from human and other mammalian sources.
Notifications to Purchaser for Creator™ products

Advantage™ products are covered by U.S. Patent #5,436,148.

Use of BD Biosciences Clontech’s Living Colors™ products containing DNA sequences coding for mutant Aequorea victoria green fluorescent protein (GFP) variants or proteins thereof requires a license from Aurora Biosciences Corporation under U.S. Patent Nos. 5,625,046, 5,777,079, 6,054,337 and other pending U.S. and foreign patent applications. In addition, certain BD Biosciences Clontech products are made under U.S. Patent No. 5,804,387 licensed from Stanford University.

Not-For-Profit research institutes or entities are granted an automatic license with the purchase of this product for use in non-commercial internal research purposes, the terms of which are disclosed in detail in the license that accompanies the shipment of this product. Such license specifically excludes the right to sell or otherwise transfer this product or its components to third parties.

For-Profit research institutes or entities that wish to use this product in non-commercial or commercial applications are required to obtain a license from Aurora Biosciences Corporation. For license information contact: Court Turner at 954-946-8416 or Fax 954-946-6743 or www.aurorabio.com. Please contact BD Biosciences Clontech directly for any other assistance, including purchasing and technical support.

All companies and institutions purchasing Living Colors™ products will be included in a quarterly report to Aurora Biosciences Corporation, as required by the BD Biosciences Clontech/Aurora license agreement.

Use of the IRES sequence is covered by U.S. Patent #5,937,190 and is limited to use solely for research purposes. Any other use of the IRES sequence requires a license from Wisconsin Alumni Research Foundation, as required by the BD Biosciences Clontech/Aurora license agreement.

Practice of the two-hybrid system is covered by U.S. Patents #5,283,173 and #5,468,614 assigned to the Research Foundation of the State University of New York. Purchase of any BD Biosciences Clontech two-hybrid reagent does not imply or convey a license to practice the two-hybrid system covered by these patents. Commercial entities purchasing these reagents must obtain a license from the Research Foundation of the State University of New York. Please contact the Research Foundation of the State University of New York for information on obtaining a license. BD Biosciences Clontech is required by its licensing agreement to submit a report of all purchasers of two-hybrid reagents to SUNY Stony Brook. Please contact Barbara A. Sawicki of SUNY Stony Brook for license information (Tel: 516-632-4162; Fax: 516-632-5983).

The PR0Net Vectors are the subjects of pending patent applications. Use of the SV40 I cloning strategy is licensed under U.S. Patent #5,959,899.

SMART™ technology is covered by U.S. Patents #5,982,271 & 5,982,272.

For Tet-based Expression Products

The use of the Tetracycline controllable expression systems (the “Tet Technology”) is covered by a series of patents including U.S. patents #5,464,756 and #5,814,618, which are proprietary to Abbott Laboratories. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. Abbott makes no warranties, express or implied or of any kind, and hereby disclaims any guarantees, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from Abbott prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression systems to Abbott. For license information, please contact:

US office: Abbott Bioscience Center
100 Research Drive, Worthington, MA 01065-4314, U.S.A., Fax: 508-755-9506

NEW PRODUCTS

For additional information visit the www.clontech.com.